NCT05242133View on ClinicalTrials.gov

Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis

PHASE3CompletedINTERVENTIONAL
Enrollment

168

Participants

Timeline

Start Date

December 20, 2017

Primary Completion Date

April 27, 2022

Study Completion Date

April 27, 2022

Conditions
Relapsing Remitting Multiple Sclerosis (RRMS)
Interventions
DRUG

Pegylated interferon beta-1a

Pegylated interferon beta-1a (CinnaGen) autoinjector (Physioject™),125 mcg, subcutaneous (SC) injection, every 2 weeks, for 24 months

DRUG

Interferon Beta-1A Prefilled Syringe

Interferon Beta-1A Prefilled Syringe, CinnoVex® (CinnaGen), 30 mcg, intramuscular injection, once a week, for 24 months

Trial Locations (1)

Unknown

Sina Hospital, Tehran

Sponsors

Lead Sponsor

Cinnagen
All Listed Sponsors
lead

Cinnagen

INDUSTRY